Reactive Dopamine Metabolites and Neurotoxicity
Parkinson’s disease occurs in approximately one percent of individuals over the age of 55. It is characterized by the presence of tremor, rigidity, and bradykinesia. Pathologically, the hallmark of Parkinson’s disease is the progressive degeneration of the dopamine (DA)-containing neurons of the nigrostriatal projection. Neurological deficits associated with the loss of DA neurons do not appear until the degeneration is extensive, presumably due to compensatory properties of the remaining DA neurons and their targets (Bernheimer et al., 1973; Zigmond et al., 1984). The mechanism responsible for the degenerative process is not known, although factors such as genetic predisposition and environmental toxins have been proposed to play a role (Agid et al., 1993). There is also growing evidence that endogenous factors such as oxidative stress and DA itself may contribute to the neurodegenerative process (Cohen, 1983; Agid et al., 1993; Zigmond et al., 1992).
KeywordsTyrosine Hydroxylase Tritium Content Striatal Slice Striatal Tissue Intrastriatal Injection
Unable to display preview. Download preview PDF.
- Agid Y., Ruberg M., Javoy-Agid R., Hirsch E., Raisman-Vozari R., Vyas S., Baucheux B., Michel P., Kastner A., Blanchard B., Damier P., Villares J. and Zhang, P. (1993) Are dopaminergic neurons selectively vulnerable to Parkinson’s disease? In: Narabayashi H., Ngatsu T., Yanagisawa N. and Mizuno, Y. (eds.), Advances in Neurology, Vol. 60, pp 148-164.Google Scholar
- Carstam R., Brinck C, Fornstedt B., Rorsman H. and Rosengren E. (1990) 5-S-Cysteinyldopac in human urine. Acta Derm. Venereol. (Stockh). 70, 373–377.Google Scholar
- Cohen G. (1983) The pathobiology of Parkinson’s disease: Biochemical aspects of dopamine neuron senescence. J. Neural Transm. 19 (Suppl), 89–103.Google Scholar
- Fornstedt B., Bergh I., Rosengren E. and Carlsson, A. (1990a) An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxypheny-lalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J. Neurochem. 54, 578–586.PubMedCrossRefGoogle Scholar
- Glantz L.A. and Lewis D.A. (1994) Synaptophysin and not Rab3A immunoreactivity is specifically reduced in the prefrontal cortex of schizophrenic subjects. Soc. Neurosci. Abstr. 20, 622.Google Scholar
- Hastings T.G., Lewis D.A. and Zigmond M.J. (1994) Intrastriatally administered dopamine: Evidence of selective neurotoxicity associated with dopamine oxidation. Soc. Neurosci. Abstr. 20, 413.Google Scholar
- Maguire M.E., Goldmann P.H. and Gilman A.G. (1974) The reaction of [3H]norepinephrine with particulate fractions of cells responsive to catecholamines. Mol. Pharmacol. 10, 563–581.Google Scholar